Valuation: Cipher Pharmaceuticals Inc.

Market Cap 338M 240M 214M 198M 180M 22.69B 342M 2.38B 933M 11.93B 902M 883M 38.01B P/E 2026 *
11.8x
P/E 2027 * 11x
Enterprise Value 338M 240M 214M 198M 180M 22.69B 342M 2.38B 933M 11.93B 902M 883M 38.01B EV / Sales 2026 *
4.77x
EV / Sales 2027 * 4.16x
Free-Float
57.46%
Yield 2026 *
-
Yield 2027 * -
1 day+0.45%
1 week-0.30%
Current month-2.49%
1 month-7.70%
3 months-19.67%
6 months-27.47%
Current year-11.62%
1 week 13.25
Extreme 13.25
13.7
1 month 13.25
Extreme 13.25
14.65
Current year 13.25
Extreme 13.25
20.56
1 year 12.48
Extreme 12.48
20.56
3 years 4.3
Extreme 4.3
20.56
5 years 1.54
Extreme 1.54
20.56
10 years 0.38
Extreme 0.38
20.56
Manager TitleAgeSince
Chief Executive Officer - 29/07/2019
Director of Finance/CFO - 10/08/2024
Director of Finance/CFO - 15/08/2022
Director TitleAgeSince
Chairman - 12/06/2019
Director/Board Member 78 21/06/2023
Director/Board Member - 21/06/2023
Date Insider Type Main position Quantity % Market Cap. Importance
30/09/26 TaxCompany -133,245 0.5243%
30/09/26 TaxCompany 133,245 0.5243%
29/09/26 Option

Director

5,000 0.0197%
Change 5-day change 1-year change 3-year change Capi.($)
+0.45%-0.30%-10.85%+197.76% 240M
-1.01%+5.13%+58.93%+117.36% 1,133B
-0.61%+1.52%+34.34%+68.48% 621B
-1.48%+0.47%+23.08%+94.76% 503B
-0.91%+2.32%+38.50%+63.54% 379B
+1.07%+1.70%+71.06%+45.98% 370B
+0.26%+1.08%+21.36%+50.60% 292B
-0.33%-1.02%+0.22%+24.44% 262B
-0.14%+2.87%+45.56%+57.22% 237B
-1.88%+0.02%+23.77%+97.39% 190B
Average -0.16%+2.86%+30.60%+81.75% 398.82B
Weighted average by Cap. +0.18%+3.73%+40.67%+79.64%

Financials

2026 *2027 *
Net sales 70.85M 50.37M 44.88M 41.55M 37.61M 4.75B 71.69M 498M 195M 2.5B 189M 185M 7.96B 81.35M 57.84M 51.54M 47.71M 43.18M 5.46B 82.32M 572M 224M 2.87B 217M 212M 9.14B
Net income 27.7M 19.69M 17.55M 16.25M 14.7M 1.86B 28.03M 195M 76.43M 977M 73.87M 72.33M 3.11B 31.76M 22.58M 20.12M 18.63M 16.86M 2.13B 32.14M 223M 87.64M 1.12B 84.7M 82.94M 3.57B
Net Debt - -
Projected Income Statement - Annual - Cipher Pharmaceuticals Inc.
Logo Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products, manages the required clinical development and regulatory approval process, and markets those products either directly or indirectly in Canada, the United States and South America. The Company's product categories include dermatology, hospital acute care, out‑licensed, and specialty medicine. Its dermatology products include Actikerall, Epuris, Vaniqa and Natroba. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Absorica (isotretinoin) is an oral retinoid. Durela, its specialty medicine, is an opioid analgesic indicated for the management of moderate to moderately severe pain in adults who require continuous treatment for several days or more. Its pipeline products include Piclidenoson CF-101, MOB-015 and DTR-001.
Employees
5
Date Price Change Volume
21/10/26 CA$13.31 +0.45% 2,988
20/10/26 CA$13.25 0.00% 11,571
19/10/26 CA$13.25 0.00% 8,408
16/10/26 CA$13.25 -2.07% 12,924
15/10/26 CA$13.53 +1.35% 9,101
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Cipher Pharmaceuticals Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
13.31CAD
Average target price
19.45CAD
Spread / Average Target
+46.13%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Cipher Pharmaceuticals Inc.